A Phase 3, Randomized, Double-Blind, Placebo-Controlled,Parallel-Design, Multinational Study to Evaluate the Efficacy and Safety of Daily Tadalafil for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia.
Phase of Trial: Phase III
Latest Information Update: 19 Apr 2016
At a glance
- Drugs Tadalafil (Primary)
- Indications Benign prostatic hyperplasia
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 19 Apr 2016 Results of a pooled analysis from four trials (n= 1462) published in the Journal of Urology
- 24 Aug 2015 Results of post-hoc analysis of pooled data from four trials published in the International Journal of Clinical Practice.
- 01 Nov 2011 Results published in the European Urology.